Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on August 12, 2025, to announce financial results and operational updates for the three and six months ended June 30, 2025. The company is a Delaware corporation headquartered in Doylestown, PA, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) containing the detailed financial data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The filing text does not contain specific quantitative comparisons to prior periods. It indicates that material operational and financial updates for the period ended June 30, 2025, are detailed in the attached press release.
Guidance, Outlook, and Risks
Management provided an update on operations for the reported period via the attached press release. The filing explicitly states that the information in Item 2.02 and the attached exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. No specific risks, contingencies, or forward-looking guidance are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash burn figures for the three and six months ended June 30, 2025.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and operational milestones.
- Verify the company's cash runway and liquidity position as disclosed in the referenced press release.
- Confirm any changes to the company's strategic outlook or capital raise plans mentioned in the operational update.